Intermittent Fasting Shows Promise for Managing Crohn's Disease Symptoms

A recent randomized controlled trial conducted by researchers at the University of Calgary has revealed that time-restricted feeding (TRF), a form of intermittent fasting, can significantly alleviate symptoms of Crohn's disease in overweight or obese adults. Published on February 9, 2026, in the journal *Gastroenterology*, the study involved 35 participants who were assigned to either an 8-hour eating window or a regular diet over a 12-week period. The results indicated a 40% reduction in disease activity and a 50% decrease in abdominal discomfort among those practicing TRF, compared to their counterparts on a standard eating schedule.

SciTechDailyHealthLineUsNews and World ReportIntermittent Fasting Reduces Crohn’s Disease Activity by 40% and Halves

The study highlighted that participants on the TRF regimen lost an average of 5.5 pounds, while those on the regular diet gained approximately 3.7 pounds. Notably, both groups consumed similar foods and caloric amounts, suggesting that the timing of meals, rather than dietary composition, played a crucial role in the observed health improvements. Researchers noted significant reductions in inflammatory markers, including leptin and plasminogen activator inhibitor-1 (PAI-1), which are linked to immune regulation and inflammation.

Intermittent Fasting Reduces Crohn’s Disease Activity by 40% and Halves

Dr. Natasha Haskey, the lead investigator, emphasized that TRF could serve as a sustainable, biologically grounded option for Crohn's patients seeking to manage their health alongside medication. The findings suggest that meal timing may influence not only symptom relief but also metabolic health and gut microbiome diversity, which are critical for maintaining remission in Crohn's disease.

SciTechDaily

Experts not involved in the study have expressed optimism regarding the findings. Dr. Sidhartha Sinha, a gastroenterologist at Stanford University, described the research as a thoughtful and encouraging step that supports existing evidence on the benefits of fasting for Crohn's patients. Similarly, Dr. Andres Hurtado-Lorenzo from the Crohn’s & Colitis Foundation noted that the study underscores the potential of dietary timing to enhance immune function and metabolic health.

HealthLine

Despite the promising results, researchers caution that larger studies are necessary to confirm the long-term safety and efficacy of TRF for broader populations with Crohn's disease. Variability in individual responses and disease phenotypes must be considered before widespread adoption of TRF protocols in clinical practice.

Intermittent Fasting Reduces Crohn’s Disease Activity by 40% and Halves

The trial marks a significant advancement in understanding how dietary interventions can impact inflammatory bowel diseases like Crohn's. By focusing on when patients eat rather than solely on what they consume, TRF presents a low-cost, accessible strategy that could revolutionize the management of Crohn's disease, particularly for those struggling with obesity. Further research is essential to validate these findings and explore the full potential of time-restricted eating in enhancing patient quality of life.

Intermittent Fasting Reduces Crohn’s Disease Activity by 40% and Halves

• “This study shows that while weight loss is an important outcome in people with overweight and Crohn’s disease, time-restricted feeding offers additional benefits beyond just the scale,” — Dr. Maitreyi Raman, Associate Professor of Medicine, University of Calgary

UsNews and World Report

• “Our research suggests time-restricted eating may be a sustainable option grounded in biology, offering patients more ways to manage their own wellness.” — Dr. Natasha Haskey, Research Associate, University of British Columbia

SciTechDaily

• “This is a thoughtful and encouraging randomized study suggesting that time-restricted eating may improve symptoms and inflammatory markers in selected patients with Crohn’s disease,” — Dr. Sidhartha Sinha, Gastroenterologist, Stanford University

HealthLine

The Crohn’s & Colitis Foundation funded the study, reflecting a commitment to innovative research in inflammatory bowel diseases. The foundation's representatives have expressed enthusiasm for the findings, highlighting the potential of TRF to provide new avenues for patient care.

SciTechDaily